CY1123344T1 - Μεθοδοι αγωγης οφθαλμικων καταστασεων με ενα εμφυτευμα κατακρατημενης απελευθερωσης φαρμακων - Google Patents
Μεθοδοι αγωγης οφθαλμικων καταστασεων με ενα εμφυτευμα κατακρατημενης απελευθερωσης φαρμακωνInfo
- Publication number
- CY1123344T1 CY1123344T1 CY20201100867T CY201100867T CY1123344T1 CY 1123344 T1 CY1123344 T1 CY 1123344T1 CY 20201100867 T CY20201100867 T CY 20201100867T CY 201100867 T CY201100867 T CY 201100867T CY 1123344 T1 CY1123344 T1 CY 1123344T1
- Authority
- CY
- Cyprus
- Prior art keywords
- corticosteroid
- conditions
- othlic
- treatment
- methods
- Prior art date
Links
- 239000007943 implant Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title 1
- 238000013269 sustained drug release Methods 0.000 title 1
- 239000003246 corticosteroid Substances 0.000 abstract 5
- 229920002988 biodegradable polymer Polymers 0.000 abstract 2
- 239000004621 biodegradable polymer Substances 0.000 abstract 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 abstract 1
- 201000011190 diabetic macular edema Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
Ενδοφθαλμικά εμφυτεύματα μπορεί να συμπεριλάβουν ένα κορτικοστεροειδές και ένα βιοαποδομήσιμο πολυμερές συσχετιζόμενο με το κορτικοστεροειδές για διευκόλυνση της αποδέσμευσης του κορτικοστεροειδούς μέσα σε έναν οφθαλμό για μια χρονική περίοδο. Σε κάποιες ενσωματώσεις, οφθαλμικές καταστάσεις, όπως είναι το διαβητικό οίδημα ωχράς κηλίδας μπορούν να υποβληθούν σε αγωγή μέσα από χορήγηση ενός ενδοφθαλμικού εμφυτεύματος συμπεριλαμβάνοντας ένα κορτικοστεροειδές και ένα βιοαποδομήσιμο πολυμερές συσχετιζόμενο με το κορτικοστεροειδές στον οφθαλμό ενός ανθρώπου σε μια συχνότητα από περίπου άπαξ κάθε έξι μήνες έως περίπου άπαξ το έτος.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361904887P | 2013-11-15 | 2013-11-15 | |
| PCT/US2014/065804 WO2015073895A1 (en) | 2013-11-15 | 2014-11-14 | Methods of treatment of ocular conditions with a sustained drug delivery implant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123344T1 true CY1123344T1 (el) | 2021-12-31 |
Family
ID=52001114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100867T CY1123344T1 (el) | 2013-11-15 | 2020-09-14 | Μεθοδοι αγωγης οφθαλμικων καταστασεων με ενα εμφυτευμα κατακρατημενης απελευθερωσης φαρμακων |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20150140062A1 (el) |
| EP (2) | EP3068403B1 (el) |
| JP (2) | JP6675307B2 (el) |
| KR (3) | KR20220082934A (el) |
| CN (1) | CN105764517A (el) |
| AU (4) | AU2014348369B2 (el) |
| CA (1) | CA2929689A1 (el) |
| CL (1) | CL2016001167A1 (el) |
| CY (1) | CY1123344T1 (el) |
| DK (1) | DK3068403T3 (el) |
| ES (1) | ES2819215T3 (el) |
| HU (1) | HUE050913T2 (el) |
| IL (2) | IL245548A0 (el) |
| MX (2) | MX2016006334A (el) |
| MY (1) | MY176039A (el) |
| NZ (1) | NZ719953A (el) |
| PH (1) | PH12016500869B1 (el) |
| PL (1) | PL3068403T3 (el) |
| PT (1) | PT3068403T (el) |
| RU (1) | RU2690841C1 (el) |
| SG (1) | SG10201809363SA (el) |
| SI (1) | SI3068403T1 (el) |
| UA (1) | UA122117C2 (el) |
| WO (1) | WO2015073895A1 (el) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3324944A4 (en) * | 2015-07-23 | 2019-04-03 | Aerie Pharmaceuticals, Inc. | INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE |
| WO2019222856A1 (en) | 2018-05-24 | 2019-11-28 | Nureva Inc. | Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones |
| AU2019275406A1 (en) | 2018-05-24 | 2020-07-16 | Celanese Eva Performance Polymers Llc | Implantable device for sustained release of a macromolecular drug compound |
| MX2020012459A (es) | 2018-05-24 | 2021-04-28 | Celanese Eva Performance Polymers Llc | Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| DK1339438T3 (da) | 2000-11-29 | 2006-02-13 | Allergan Inc | Forebyggelse af transplantatafvisning i ojet |
| US20050048099A1 (en) * | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US20050244500A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US20090082321A1 (en) * | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Steroid containing drug delivery systems |
| CN103402582A (zh) * | 2011-02-11 | 2013-11-20 | 普西维达公司 | 使用抗水肿疗法治疗黄斑水肿的方法 |
-
2014
- 2014-11-14 MY MYPI2016000899A patent/MY176039A/en unknown
- 2014-11-14 RU RU2016119132A patent/RU2690841C1/ru active
- 2014-11-14 SG SG10201809363SA patent/SG10201809363SA/en unknown
- 2014-11-14 UA UAA201605224A patent/UA122117C2/uk unknown
- 2014-11-14 PT PT148057680T patent/PT3068403T/pt unknown
- 2014-11-14 EP EP14805768.0A patent/EP3068403B1/en active Active
- 2014-11-14 JP JP2016530991A patent/JP6675307B2/ja active Active
- 2014-11-14 AU AU2014348369A patent/AU2014348369B2/en active Active
- 2014-11-14 KR KR1020227018854A patent/KR20220082934A/ko not_active IP Right Cessation
- 2014-11-14 MX MX2016006334A patent/MX2016006334A/es unknown
- 2014-11-14 EP EP20173457.1A patent/EP3714875A1/en active Pending
- 2014-11-14 CA CA2929689A patent/CA2929689A1/en active Pending
- 2014-11-14 US US14/542,189 patent/US20150140062A1/en active Pending
- 2014-11-14 ES ES14805768T patent/ES2819215T3/es active Active
- 2014-11-14 KR KR1020167015466A patent/KR102475746B1/ko active IP Right Grant
- 2014-11-14 HU HUE14805768A patent/HUE050913T2/hu unknown
- 2014-11-14 NZ NZ719953A patent/NZ719953A/en unknown
- 2014-11-14 CN CN201480062403.7A patent/CN105764517A/zh active Pending
- 2014-11-14 PL PL14805768T patent/PL3068403T3/pl unknown
- 2014-11-14 DK DK14805768.0T patent/DK3068403T3/da active
- 2014-11-14 WO PCT/US2014/065804 patent/WO2015073895A1/en active Application Filing
- 2014-11-14 SI SI201431652T patent/SI3068403T1/sl unknown
- 2014-11-14 KR KR1020247013455A patent/KR20240058976A/ko active Search and Examination
-
2016
- 2016-05-09 IL IL245548A patent/IL245548A0/en unknown
- 2016-05-11 PH PH12016500869A patent/PH12016500869B1/en unknown
- 2016-05-13 CL CL2016001167A patent/CL2016001167A1/es unknown
- 2016-05-13 MX MX2022002306A patent/MX2022002306A/es unknown
-
2019
- 2019-12-13 JP JP2019225503A patent/JP7022735B2/ja active Active
-
2020
- 2020-06-30 AU AU2020204362A patent/AU2020204362A1/en not_active Abandoned
- 2020-09-14 CY CY20201100867T patent/CY1123344T1/el unknown
-
2022
- 2022-02-23 IL IL290837A patent/IL290837A/en unknown
- 2022-06-29 AU AU2022204607A patent/AU2022204607A1/en not_active Abandoned
-
2024
- 2024-08-09 AU AU2024205640A patent/AU2024205640A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123344T1 (el) | Μεθοδοι αγωγης οφθαλμικων καταστασεων με ενα εμφυτευμα κατακρατημενης απελευθερωσης φαρμακων | |
| CY1121064T1 (el) | Μειωση ενδοφθαλμιας πιεσης με ενδοθαλαμικα εμφυτευματα βιματοπροστης | |
| CY1122122T1 (el) | Υδατικο οφθαλμικο διαλυμα και μεθοδος για τη θεραπευτικη αγωγη συνδρομου ξηρου οφθαλμου | |
| CY1121511T1 (el) | Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων | |
| CY1120393T1 (el) | Κρυσταλλικες μορφες διαμορφωτη υποδοχεα ανδρογονων | |
| BR112017024531A2 (pt) | lentes intraoculares ajustáveis por luz usando nanopartículas de conversão ascendente e luz do infravermelho próximo (nir) | |
| BR112016028964A2 (pt) | métodos de tratamento com antagonistas contra pd-1 e pd-l1 em combinação com terapia de radiação | |
| AR091237A1 (es) | Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf) | |
| CY1121787T1 (el) | Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων | |
| ECSP12011692A (es) | Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos | |
| BR112015019546A2 (pt) | implante de distribuição de drogas prolongado | |
| EA201690967A1 (ru) | Глазное устройство | |
| BR112015006929A2 (pt) | sistemas de distribuição de droga biodegradável para liberação sustentada de proteínas | |
| CY1120642T1 (el) | Φαρμακευτικη συνθεση της ιβουπροφαιμνης και της τραμαδολης για οφθαλμολογικη χρηση | |
| AR088585A1 (es) | Un medicamento para tratar la enfermedad del ojo anterior | |
| CY1121000T1 (el) | Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων | |
| CL2016002827A1 (es) | Sistema para limpiar una región ocular, que comprende a un aplicardor que consiste de una primera y segunda camara, un elemento sellable que divide la primera y segunda camara, donde la segunda camara contiene una composicion ocular y b un surtidor kit y metodos de tratamientos. | |
| CO2017012573A2 (es) | Formación de nanopartículas de ciclosporina a/ciclodextrina | |
| PH12015502469A1 (en) | Fcrn-binding abolished anti-igf-ir antibodies and their use in the treatment of vascular eye diseases | |
| EA201692402A1 (ru) | Лекарственные формы для местного применения и их использование | |
| MX2016016090A (es) | Composicion oftalmica para el tratamiento de infeccion ocular. | |
| UY33153A (es) | Formulación tópica oftálmica de péptidos | |
| BR112017007095A2 (pt) | conjugados e derivados de prostaglandina para tratamento de glaucoma e hipertensão ocular | |
| BR112014020424A2 (pt) | ponta de fragmentação, dispositio de cirurgia intra-ocular fornecido com as mesmas, método para suprimir ocorrência de cavitação e método de cirurgia de catarata | |
| BR112018006474A2 (pt) | nova composição oftalmológica compreendendo rebamipide e método para preparar o mesmo |